Fig. 3: Expression of nuclear TCA dehydrogenase maintains the contractility of iPSC-CMs.
From: Nuclear translocation of mitochondrial dehydrogenases as an adaptive cardioprotective mechanism
a, b Calcium handling as assessed by Fluo-4 staining in cells expressing nuclear IDH-2 in the presence of DRN. IDH-2 expression in the nucleus prior to DRN treatment maintains the rhythmic change in calcium (a, b). n = 3 P value ****<0.0001, *<0.05. c–h Representative graph for contraction and relaxation cycle of cardiomyocyte contractility (c), quantification of beat rate (d), contraction velocity (e), relaxation velocity (f), maximum contraction (g), and maximum relaxation (h) in cells expressing nuclear IDH-2 prior to DRN treatment compared to control cells treated with DRN. n = 3 P value ****<0.0001, ***<0.0005, **<0.005. *=0.0399, i Representative M-mode images of DRN- or PBS-treated mice. j Left ventricle ejection fraction percentage and k fractional shortening recorded from M-mode tracings in mice treated with DRN or PBS. n = 3 P value*** <0.001. l Representative M-mode images of DRN-treated mice injected with GFP- or NLS-IDH2-expressing lentivirus. m Left ventricle ejection fraction percentage and n fractional shortening recorded from M-mode tracings in mice expressing GFP or NLS-IDH-2 prior to DRN treatment. P value *<0.05. n = 5 (GFP, both male and female), n = 8 (NLS-IDH-2, both male and female).
